Barbara-Jean Bormann-Kennedy Sells 16,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares in the company, valued at $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Up 0.5%

NASDAQ:XERS traded up $0.03 during trading hours on Friday, hitting $6.18. 1,028,207 shares of the company traded hands, compared to its average volume of 1,829,779. Xeris Biopharma Holdings, Inc. has a one year low of $4.30 and a one year high of $10.08. The company has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The firm’s 50-day simple moving average is $6.08 and its 200-day simple moving average is $6.60. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its holdings in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock valued at $5,072,000 after acquiring an additional 156,483 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after purchasing an additional 225,602 shares during the period. California State Teachers Retirement System boosted its stake in shares of Xeris Biopharma by 19.3% during the 1st quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock valued at $1,046,000 after purchasing an additional 29,168 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Xeris Biopharma by 12.9% during the 1st quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock valued at $253,000 after purchasing an additional 4,974 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Xeris Biopharma by 59.0% during the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock valued at $422,000 after buying an additional 27,003 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on XERS. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.